These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 28778961)

  • 21. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
    Bergstrom RT; Silverman DA; Chambers K; Kim JA
    Otolaryngol Head Neck Surg; 2004 Jan; 130(1):94-103. PubMed ID: 14726917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses.
    Garbe Y; Klier U; Linnebacher M
    BMC Cancer; 2011 Sep; 11():410. PubMed ID: 21943054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inducing a humoral immune response to pancreatic cancer antigen.
    Seifert M; Seifert G; Wolff-Vorbeck G; Langenmair E; Hopt UT; Wittel UA
    Cell Immunol; 2016 Dec; 310():150-155. PubMed ID: 27663207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modern strategies and capabilities for activation of the immune response against tumor cells.
    Sennikov SV; Khantakova JN; Kulikova EV; Obleukhova IA; Shevchenko JA
    Tumour Biol; 2017 May; 39(5):1010428317698380. PubMed ID: 28513301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
    Lizée G; Gonzales MI; Topalian SL
    Hum Gene Ther; 2004 Apr; 15(4):393-404. PubMed ID: 15053864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
    Ren H; Zhao S; Li W; Dong H; Zhou M; Cao M; Hu HM; Wang LX
    J Immunother; 2014 Oct; 37(8):383-93. PubMed ID: 25198526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
    Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.
    Bai L; Beckhove P; Feuerer M; Umansky V; Choi C; Solomayer FS; Diel IJ; Schirrmacher V
    Int J Cancer; 2003 Jan; 103(1):73-83. PubMed ID: 12455056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.